Showing 1701-1710 of 2314 results for "".
- Stealth BioTherapeutics Doses First Patient in Phase 2 Study of Elamipretide for the Treatment of Dry AMDhttps://modernod.com/news/stealth-biotherapeutics-announces-dosing-of-first-patient-in-phase-2-study-of-elamipretide-for-the-treatment-of-dry-amd/2476423/Stealth BioTherapeutics announced that it has dosed the first patient in ReCLAIM-2, a phase 2 study of elamipretide in patients with dry age-related macular degeneration (AMD) with geographic atrophy. “People with dry AMD can ultimately lose central vision. However, long before that
- Dompé Receives Industry Innovation Award for Oxervate Eye Drops for Neurotrophic Keratitishttps://modernod.com/news/dompe-receives-industry-innovation-award-for-oxervate-eye-drops-for-neurotrophic-keratitis/2476372/Dompé Farmaceutici S.p.A and Dompé US Inc. announced that the National Organization for Rare Disorders (NORD) has awarded them the 2019 Industry Innovation Award for Oxervate. The Rare Impact Awards celebrate people, organizations, and innovators making exceptional contributions benefiting rare d
- ProQR Reports First Patient Dosing in Phase 1/2 STELLAR Trial of QR-421a for Usher Syndrome Type 2https://modernod.com/news/proqr-reports-first-patient-dosing-in-phase-1-2-stellar-trial-of-qr-421a-for-usher-syndrome-type-2/2476365/ProQR Therapeutics announced the first patient dosed in the phase 1/2 STELLAR clinical trial for QR-421a in patients with Usher syndrome type 2 or non-syndromic retinitis pigmentosa (RP). Interim data from the study are expected to be announced mid-2019. “There are no effective treat
- New Laser Helps Doctors Image Full Eye in 3Dhttps://modernod.com/news/new-laser-helps-doctors-image-full-eye-in-3d/2476348/Scientists have developed a laser-based technique that can produce a full 3D image of all the layers of the retina, allowing doctors to better diagnose and treat eye diseases such as cataracts, diabetic retinopathy, and cancer, according to an Octlight news release. Researchers from the Te
- TopiVert Announces First Patients Dosed in THEIA-1 Phase 2b/3 Study of Dry Eye Disease Treatmenthttps://modernod.com/news/topivert-announces-first-patients-dosed-in-theia-1-phase-2b-3-study-of-dry-eye-disease-treatment/2476259/TopiVert Pharma announced that the first patients have been dosed in the THEIA-1 phase 2b/3 clinical study evaluating TOP1630, a novel anti-inflammatory kinase inhibitor, as an ophthalmic solution for the treatment of dry eye disease. THEIA-1 is a multicenter, randomised, double-masked, pl
- Ocular Therapeutix Announces Dosing of First Patient in Phase 1 Clinical Trial for the Treatment of Wet AMDhttps://modernod.com/news/ocular-therapeutix-announces-dosing-of-first-patient-in-phase-1-clinical-trial-for-the-treatment-of-wet-amd/2476273/Ocular Therapeutix announced the dosing of the first patient in a phase 1 trial of OTX-TKI (tyrosine kinase inhibitor implant) in patients with wet age-related macular degeneration (AMD). The first patient was dosed at the Sydney Retina Clinic in Sydney, Australia. “We are excited to annou
- New Medscape Report Finds More Than One in Three Doctors are Burned Outhttps://modernod.com/news/new-medscape-report-finds-more-than-one-in-three-doctors-are-burned-out/2476292/Burnout and depression are having a significant effect on the global medical community, as demonstrated by Medscape’s Global Physicians’ Burnout and Lifestyle Comparisons report. Nearly 20,000 doctors in six countries (France,
- Silgan to Debut Iridya Preservative-Free Multi-dose Eye Dropperhttps://modernod.com/news/silgan-to-debut-iridya-preservative-free-multi-dose-eye-dropper/2476322/Silgan Dispensing will highlight its newest ophthalmic dispensing solution, Iridya, at this year’s Pharmapack, Europe’s dedicated pharmaceutical packaging and drug delivery event. Iridya is a next-generation, preservative-free multi-dose, eye dropper that improves on existing technology by
- CorneaGen to Acquire KeraLink Domestic Eye Bank Operationshttps://modernod.com/news/corneagen-to-acquire-keralink-domestic-eye-bank-operations/2476326/CorneaGen and KeraLink International, a provider of corneal transplantation services, supplies and grafts for transplant, have signed a final agreement for CorneaGen to acquire KeraLink’s domestic eye bank operations and related assets. Financial terms of the deal were not disclosed. <
- Controlled Trial Shows Promise of Donated Stem Cells in Restoring Visionhttps://modernod.com/news/controlled-trial-shows-promise-of-donated-stem-cells-in-restoring-vision/2476345/A study in STEM CELLS Translational Medicine provides a deeper and clearer understanding of how patients suffering vision loss in both eyes due to limbal stem cell deficiency (LSCD) might benefit from a stem cell transplant using donated cells. This is the first ra